Keros Therapeutics Inc (KROS) returns
Keros Therapeutics returns over 5 years
$1,000 invested in Keros Therapeutics five years ago was worth $264.62 at the close on October 30, 2026, with dividends reinvested: an average return of -23.3% a year. The same $1,000 in the S&P 500 (SPY) became $1,760.
Total return by period
| Period | Total return | A year, on average | $1,000 became | S&P 500 (SPY) |
|---|---|---|---|---|
| 1 month | -3.2% | — | $968.42 | -0.9% |
| 3 months | +8.0% | — | $1,080 | +2.1% |
| Year to date | -45.8% | — | $542.24 | +11.7% |
| 1 year | -26.5% | — | $734.53 | +12.4% |
| 3 years | -60.6% | -26.7% | $394.00 | +88.5% |
| 5 years | -73.5% | -23.3% | $264.62 | +76.0% |
Keros Therapeutics return by calendar year
| Year | KROS | S&P 500 (SPY) | Difference |
|---|---|---|---|
| 2026 to date | -45.8% | +11.7% | -57.5% |
| 2025 | +28.6% | +17.7% | +10.9% |
| 2024 | -60.2% | +24.9% | -85.1% |
| 2023 | -17.2% | +26.2% | -43.4% |
| 2022 | -17.9% | -18.2% | +0.2% |
| 2021 | -17.1% | +28.7% | -45.8% |
Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.
See also: KROS financials
No forecast, no recommendation. This page describes Keros Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.